Purpose

This study is exploring the efficacy of a digital therapeutic app in reducing symptoms of posttraumatic stress disorder (PTSD) in adults.

Conditions

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Posttraumatic stress disorder (PTSD) diagnosis - Anxiety Sensitivity Index 3 (ASI-3) scores above 24 - PTSD Checklist for DSM-V (PCL-5) scores above 30 - Understands and speaks English - Access to a smartphone that is connected to the internet

Exclusion Criteria

  • Score of 24 or lower on the ASI-3 - Score of 30 and below on the PCL-5 - No PTSD diagnosis - Active psychosis - Acute intoxication during study baseline - Enrolled in another treatment research study - Medical illness that would prevent the completion of interoceptive exposure exercises

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Single (Participant)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
OTX-601
A prescription digital therapeutic designed to overcome existing barriers and deliver evidence based treatment for PTSD
  • Device: OTX-601 Digital Therapeutic
    Prescription digital therapeutic designed to overcome existing barriers and deliver evidence-based treatment for PTSD
Sham Comparator
OTX-003
OTX-003 is a smartphone application developed as a comparator to OTX-601 and designed to match its interface while providing no active PTSD treatment.
  • Device: OTX-003 Comparator app
    Comparator designed to match interface of intervention while providing no active treatment.

Recruiting Locations

More Details

Status
Recruiting
Sponsor
Oui Therapeutics, Inc.

Study Contact

Brian Keenaghan
203-200-0482
brian@ouitherapeutics.com

Detailed Description

The purpose of this study is to conduct a randomized controlled trial to evaluate the efficacy of OTX-601 (intervention) compared to OTX-003 (comparator) in reducing PTSD symptoms from baseline to 7 weeks.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.